CorMedix reverses 2024 loss as DefenCath sales and Melinta acquisition fuel growth
CorMedix (NASDAQ:CRMD) reported a significant return to profitability for the fourth quarter on Thursday, as the commercial rollout of its lead product, DefenCath, gained momentum alongside contributions from its newly acquired Melinta Therapeutics portfolio.

_1354341_640x360_2490708547845-640x360.jpg&w=1200&q=75)

_1354281_640x360_2490710083504-640x360.jpg&w=1200&q=75)

-640x360.jpg&w=1200&q=75)
-640x360.jpg&w=1200&q=75)













